Clinical Trial Update: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating adding duvelisib or CC-486 to standard therapy for several peripheral T-cell lymphomas has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Follicular T-cell Lymphoma
• Mature T-cell and Nk-cell Non-hodgkin Lymphoma
• Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
• Nodal Peripheral T-cell Lymphoma with Tfh Phenotype
• Peripheral T-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• CC-486 (oral azacitidine) (azacitidine)
• Duvelisib (Copiktra) (duvelisib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Status: SUSPENDED